Pharamacogenomics is related to personalized medicine, many companies have started thinking in that way for bringing up personalized therapy. Amgen with its operations in Seattle and Cambridge, MA, has specially designed cancer drugs for specific genetic subgroups and it has performed clinical trial for this.Amgen said that its marketed anti-tumour drug, panitumumab (Vectibix) controls tumour growth for a significantly longer time for colon cancer patients with a normal form of a gene called KRAS, compared to patients with more aggressive, mutated form of the gene. The study was carried out in a group of 1,100 patients.....This is just the beginning....We have more to watch :)
No comments:
Post a Comment